Literature DB >> 2454606

Plasmapheresis alleviates neuropathy accompanying IgM anti-myelin-associated glycoprotein paraproteinemia.

D C Haas1, A H Tatum.   

Abstract

A patient with peripheral neuropathy accompanying a benign IgM anti-myelin-associated glycoprotein paraproteinemia has been treated successfully by plasmapheresis for over a year, and during this time, fluctuations in the patient's symptoms and signs have correlated with variations in the serum IgM level. These results suggest that plasmapheresis may be more beneficial for such neuropathies than indicated previously, and they add to the evidence implicating the paraprotein as the cause of the neuropathy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454606     DOI: 10.1002/ana.410230415

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  16 in total

Review 1.  Relationship between autoantibody specificities and peripheral nervous system involvements.

Authors:  M O Jauberteau-Marchan
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

2.  Successful treatment of IgM paraproteinaemic neuropathy with fludarabine.

Authors:  H C Wilson; M P Lunn; S Schey; R A Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-05       Impact factor: 10.154

3.  The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings.

Authors:  K B Yeung; P K Thomas; R H King; H Waddy; R G Will; R A Hughes; N A Gregson; S Leibowitz
Journal:  J Neurol       Date:  1991-10       Impact factor: 4.849

4.  Proximal motor neuropathy, IgA paraproteinaemia and anti-myelin-associated glycoprotein reactivity.

Authors:  T Hemachudha; P Phanuphak; K Phanthumchinda; S Kasempimolporn
Journal:  Postgrad Med J       Date:  1989-09       Impact factor: 2.401

Review 5.  Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.

Authors:  Michael Pt Lunn; Eduardo Nobile-Orazio
Journal:  Cochrane Database Syst Rev       Date:  2016-10-04

Review 6.  Glycosphingolipids as potential diagnostic markers and/or antigens in neurological disorders.

Authors:  P Fredman; A Lekman
Journal:  Neurochem Res       Date:  1997-08       Impact factor: 3.996

7.  Human monoclonal IgM with autoantibody activity against two gangliosides (GM1 and GD1b) in a patient with motor neuron syndrome.

Authors:  M O Jauberteau; N Gualde; J L Preud'Homme; M Rigaud; R Gil; J M Vallat; N Baumann
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

8.  Immunochemical and clinical effects of immunosuppressive treatment in monoclonal IgM neuropathy.

Authors:  J H Ernerudh; M Vrethem; O Andersen; C Lindberg; G Berlin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

9.  IgG monoclonal paraproteinaemia and peripheral neuropathy.

Authors:  A F Bleasel; S H Hawke; J D Pollard; J G McLeod
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-01       Impact factor: 10.154

10.  Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.

Authors:  John P Bida; Robert A Kyle; Terry M Therneau; L Joseph Melton; Matthew F Plevak; Dirk R Larson; Angela Dispenzieri; Jerry A Katzmann; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2009-08       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.